









Markets
/
Stocks
/
nasdaq-entx
/

Entera Bio Ltd

ENTX

1.040USD

-0.130-11.11%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

47.49MMarket Cap

LossP/E TTM



Entera Bio Ltd

1.040

-0.130-11.11%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Entera Bio Ltd

Currency: USD Updated: 2026-02-06

Key Insights

Entera Bio Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 142 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.00.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Entera Bio Ltd's Score

Industry at a Glance

Industry Ranking

142 / 392

Overall Ranking

287 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Entera Bio Ltd Highlights

StrengthsRisks

Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 35.07% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 181.00K.

Fairly Valued

The company’s latest PE is -4.26, at a medium 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 88.40K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.48.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

10.000

Target Price

+754.70%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Entera Bio Ltd is 6.54, ranking 242 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 5.93%.

Score

Industry at a Glance

Previous score

6.47

Change

0.07



Financials

9.30

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.94

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.13

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Entera Bio Ltd's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Entera Bio Ltd is 6.37, ranking 288 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -4.26, which is -62.52% below the recent high of -1.60 and -187.28% above the recent low of -12.25.

Score

Industry at a Glance

Previous score

6.37

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 142/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Entera Bio Ltd is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 10.00, with a high of 10.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

10.000

Target Price

+754.70%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Entera Bio Ltd

ENTX

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Entera Bio Ltd is 6.69, ranking 191 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.56 and the support level at 0.76, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.90

Change

-0.21

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.056

Sell

RSI(14)

22.334

Sell

STOCH(KDJ)(9,3,3)

11.043

Oversold

ATR(14)

0.137

Low Volatility

CCI(14)

-152.451

Sell

Williams %R

94.406

Oversold

TRIX(12,20)

-1.363

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.194

Sell

MA10

1.335

Sell

MA20

1.457

Sell

MA50

1.781

Sell

MA100

2.078

Sell

MA200

2.035

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Entera Bio Ltd is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 22.66%, representing a quarter-over-quarter decrease of 0.00%. The largest institutional shareholder is Steven Cohen, holding a total of 1.18M shares, representing 2.57% of shares outstanding, with 56.70% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Knoll Capital Management, LLC

5.88M

OPKO Health Inc

3.87M

+4.88%

D.N.A Biomedical Solutions, Ltd.

3.73M

Centillion Fund Inc

2.40M

Point72 Asset Management, L.P.

Star Investors

1.18M

-56.31%

Marshall Wace LLP

627.33K

Schonfeld Strategic Advisors LLC

566.96K

-6.21%

Lieberman (Gerald M)

324.96K

Toledano (Miranda Jayne)

302.45K

+3.77%

Parkman Healthcare Partners LLC

280.82K

-21.08%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Entera Bio Ltd is 2.18, ranking 249 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.86. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.